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Abstract
Tau aggregation is a hallmark of a group of neurodegenerative diseases termed Tauopathies. Reduction of aggregation-prone Tau
has emerged as a promising therapeutic approach. Here, we show that an anti-aggregant Tau fragment (F3ΔKPP, residues 258–
360) harboring theΔK280 mutation and two proline substitutions (I277P & I308P) in the repeat domain can inhibit aggregation of
Tau constructs in vitro, in cultured cells and in vivo in a Caenorhabditis elegans model of Tau aggregation. The Tau fragment
reduced Tau-dependent cytotoxicity in a N2a cell model, suppressed the Tau-mediated neuronal dysfunction and ameliorated the
defective locomotion in C. elegans. In vitro the fragment competes with full-length Tau for polyanionic aggregation inducers and
thus inhibits Tau aggregation. Our combined in vitro and in vivo results suggest that the anti-aggregant Tau fragment may
potentially be used to address the consequences of Tau aggregation in Tauopathies.
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Introduction
The aggregation of the microtubule-associated protein Tau is a
hallmark of Alzheimer disease and a number of other neuro-
degenerative diseases collectively termed Tauopathies. The
nature of the Tau species (monomers vs. oligomers vs. fibers)
that are the real culprits remains a matter of debate, but the
process of Tau aggregation is generally linked to neurodegen-
eration [1, 2]. Thus, suppressing Tau levels and Tau aggrega-
tion has emerged as a promising therapeutic approach for
treatment of Tauopathies [3, 4].
Tau is a natively unfolded protein, which exhibits very little
tendency for aggregation on its own. Despite the fact that Tau
can be induced to aggregate in vitro with the aid of polyanions,
the trigger for Tau aggregation in vivo still remains unclear.
Nevertheless, it is known that the aggregation of Tau is regu-
lated by two hexapeptide motifs with enhanced β-propensity
(275VQIINK280 and 306VQIVYK311) in the second and third
repeat of Tau [5]. Some Tau mutations in frontotemporal de-
mentia (FTD) (e.g., ΔK280 & P301L) enhance β-propensity
of the two hexapeptides and accordingly promote Tau
aggregation[6]. By contrast, disruption of β-propensity via in-
troducing two proline residues, known as β-structure breakers,
into these hexapeptides (VQPINK & VQPVYK) prevents Tau
aggregation and its toxicity [7]. Given their critical role in
aggregation, the two hexapeptides become targets for develop-
ing inhibitors of Tau aggregation. Indeed, based on the struc-
ture of the two hexapeptides, a computer-aided design success-
fully identified several peptides showing high affinity to the
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two motifs, which inhibit Tau aggregation and thereby mani-
fest therapeutic potential [8]. Similarly the inhibition of aggre-
gation of other amyloidogenic proteins, such as Aβ, α-
synuclein and prion protein can be achieved using β-sheet
breaker peptides, i.e., peptides that are homologous to the
targeted proteins but contain proline residues that interrupt
the β-sheet structure [9, 10]. Although the introduction of
proline into the hexapeptides can prevent self-aggregation
of Tau in vitro and in vivo, it is not clear whether such β-
breaker peptides of Tau can act as inhibitors of Tau aggre-
gation and toxicity in cell and animal models.
Peptide-based therapy has been under consideration for
some time; however, the nature of peptides—rapid degrada-
tion by proteases, low permeability across biological barriers
(e.g., blood-brain barrier (BBB)) are intrinsic weaknesses that
retard its therapeutic applications [11]. Nonetheless, recent
years have seen a renaissance in gene therapy owing to the
development of new technologies, e.g., genome editing tools
(e.g., CRISPR-Cas9), and safer viral carriers (e.g., adeno-
associated virus (AAV) and lentivirus) for delivery of genes
into targeted cells (AAV) [12]. Our previous studies showed
that the expression of anti-aggregant Tau in cultured cells or in
transgenic mice does not cause overt side effects [13–15].
Thus in this study, we test whether a β-sheet breaker Tau
fragment can inhibit Tau aggregation and thereby be poten-
tially used for therapies for AD and other Tauopathies.
Materials and Methods
Cell Culture, Transfection and Treatments
The inducible Tet-On mouse neuroblastoma cell line (N2a)
was generated as previously described [13]. The cells were
cultured in Eagle’s minimum essential medium (MEM) sup-
plemented with 10% fetal bovine serum (FBS), 0.1% nones-
sential amino acids, and 600 μg/ml G418. The expression of
Tau was induced with 1 μg/ml doxycycline. Transfection of
N2a cells were performed with lipofectamine 2000
(Invitrogen) according to the manufacturer’s manual.
Twenty-four hours later, the conditioned medium was re-
moved, and the cells were washed with warm PBS and then
incubated in culture medium supplemented with 1 μg/ml
doxycycline for 2 days to induce Tau expression.
Protein Preparation
Full-length Tau construct hTau40, TauRD construct (also
known as K18, residues 244–372, comprising the four-
repeat domain of Tau) harboring an FTDP-17 mutation
ΔK280 (TauRDΔK) and its fragment F3ΔKPP (residues 258–
360, harboring ΔK280 with I177 and I308 in the two
hexapeptide motifs at the second and third repeat domain of
Taumutated to proline) were prepared as described previously
[16, 17] (Fig. 1). Tau constructs were obtained in expression
vector pNG2 (a derivative of pET-3a (Merck-Novagen),
employing site-directed mutagenesis using the QuickChange
site-directed mutagenesis method (Stratagene). Recombinant
proteins were expressed in the Escherichia coli BL21 (DE3)
strain (Merck-Novagen). The expressed proteins were puri-
fied from bacterial extracts by using the heat stability of Tau
protein and by FPLC SP-Sepharose (GE Healthcare). The cell
pellet was resuspended in extraction buffer (50 mM MES,
500 mM NaCl, 1 mM MgSO4, 1 mM EGTA, and 5 mM
DTT, pH 6.8) supplemented with a protease inhibitor mixture
(Roche Applied Science). The cells were disrupted with a
French pressure cell and subsequently boiled for 20 min.
The extracts were isolated by centrifugation, and the superna-
tant was dialyzed against cation exchange chromatography
buffer A (20 mM MES, 50 mM NaCl, 1 mM MgSO4,1 mM
EGTA, 2 mMDTT, and 0.1 mMPMSF, pH 6.8) for two times
and loaded on a FPLC SP-Sepharose column. The protein was
eluted with a linear gradient of cation exchange chromatogra-
phy buffer B (20 mMMES, 1 M NaCl, 1 mMMgSO4, 1 mM
EGTA, 2 mMDTT, and 0.1 mMPMSF, pH 6.8). The purity of
proteins was ascertained by SDS-PAGE. Where necessary,
breakdown products were removed by using the additional
gel filtration column Superdex G75 with PBS buffer
(137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, and 1 mM DTT, pH 7.4).
Fig. 1 Constructs of Tau. The top bar diagram represents the longest
isoform of the human Tau40 (441 residues). The diagram below
hTau40 shows the four-repeat construct TauRD. The two hexapeptides
(275VQIINK280 and 306VQIVYK311) are the motifs with the highest β-
propensity at the beginning of the 2nd and 3rd repeat domains. The
construct TauRDΔK contains the FTDP-17 mutation ΔK280 that
accelerates aggregation by promoting the β-structure (pro-aggregant
mutant). The construct F3ΔK is a proteolytic Tau fragment composed of
aa. 258–360 [17, 18]. The construct F3ΔK-PP harborsΔK280 and has two
proline mutations (I277P and I308P in the hexapeptide motifs) that inhibit
aggregation by disrupting the β-structure (anti-aggregant mutant)
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ThS Fluorescence
TauRDΔK protein was dissolved at a concentration of 10 μM
in PBS buffer supplemented with 2.5 μM heparin (Sigma,
H3393, > 180 USP/mg, ~ MW 16 K), 1 mM dithiothreitol
(DTT) and 40 μM thioflavine S (ThS). Different concentra-
tions of F3ΔKPP (0, 10, 20, 40, and 80 μM) were mixed to
the reaction mixture and the Kinetics of ThS fluorescence
measured in a Tecan spectrofluorometer with an excitation
wavelength of 440 nm and an emission wavelength of
521 nm (slit width, 2.5 nm each) in a black 384-well micro-
titer plate with round wells (Thermo Labsystems) using
Magellan software. Measurements were carried out at
37 °C, and the background fluorescence was subtracted
from respective blanks.
Pelleting Assay
The aggregated samples were centrifuged at 61000 rpm
(100,000×g; TLA.100.3 rotor) to generate pellet fraction of
aggregated Tau protein. The pellet was resuspended in the
same volume as supernatant. The samples were run on a
17% SDS-PAGE gel and the amount of Tau protein in the
supernatants and pellets were quantified by densitometry of
the Coomassie Brilliant Blue R-250 stained gels using ImageJ
analysis software.
Atomic Force Microscopy
One to two micromolar of Tau protein (after 24 h of TauRDΔK
aggregation (10 μM)) was diluted in PBS and placed on fresh-
ly cleaved mica for 10 min. The excess unbound protein was
washed with PBS three times and the mica was filled with
imaging buffer (10 mM Tris-HCl, pH 7.4, 50 mM KCl).
AFM imaging was performed in oscillation mode using a
Nano Wizard Ultra-speed AFM microscope (JPK instru-
ments) and Si3N4 cantilevers (NPS series, Bruker) with
spring constants of 0.1–0.6 N/m. Drive frequency of the can-
tilever tip was set using in-built auto-tune option. Surface
approach was performed at 0.7 V. Later on, to achieve mini-
mal imaging forces between AFM stylus and sample and also
to compensate for the thermal drift of the AFM, the amplitude
set point was adjusted manually. The acquired images were
processed using JPK data processing software.
Electron Microscopy
Ten microliters of the samples (after performing the turbidity
assay to monitor microtubule assembly) were incubated on
glow discharged 200 mesh carbon-coated copper grids for
3 min followed by washing thrice with RB buffer and nega-
tively stained with 2% filtered uranyl acetate for 30 s. Excess
uranyl acetate was washed once with H2O. The specimens
were examined with a JEOL electron microscope at 200 kV
at the electron imaging facility of CAESAR. Images of the
microtubules were captured with a CCD camera using
EMMENU 4 software.
Biochemical Assays
For solubility assays, cells were collected by centrifugation at
1000×g for 5 min. The levels and solubility of different Tau
constructs were determined by sarkosyl extraction as previ-
ously described [17]. Supernatant and sarkosyl insoluble pel-
let samples were analyzed by Western blotting. The sarkosyl
insoluble pellets and supernatants were loaded at 60:1
(pellet:supernatant). For quantification of Tau levels, the
Western blots were probed with pan-Tau antibody K9JA
(A-0024, DAKO, Glostrup, Denmark) and analyzed by
densitometry.
Cytotoxicity Assays
Cytotoxicity was assessed by a LIVE-DEAD assay kit
(Molecular Probes, Eugene, OR). For the LIVE-DEAD assay,
N2a cells seeded on the coverslips were induced to express
Tau constructs for 2 days. EthD (5 mM; Molecular Probes)
was added to the medium to a final concentration of 2 μM and
incubated at 37 °C for 30 min. Cells were fixed with 4%
paraformaldehyde in PBS for 15 min and processed for
immunofluorescence.
Immunofluorescence
Inducible N2a cells were either singly transfected with
pBI5 plasmids encoding TauRDΔK or F3ΔKPP or co-
transfected with these two plasmids. After 1 day, cells
were induced to express Tau with 1 μg/ml doxycycline
for 2 days. The cells on the coverslips were fixed with
4% paraformaldehyde in PBS for 15 min, then perme-
abilized with 0.1% triton at room temperature for
10 min, incubated with 0.1% ThS for 5 min, and washed
three times in 50% ethanol. Samples were blocked in 5%
BSA for 1 h at room temperature, followed by incubation
with the primary and secondary antibodies. Confocal im-
ages were captured with a LSM700 microscope (Zeiss,
Oberkochen, Germany).
Immunoprecipitation
Immunoprecipitation was done as described previously
with slight modifications [17]. N2a cells were co-
transfected with TauRDΔK-His and F3ΔKPP or hTau40
and F3ΔKPP and induced to express Tau for 2 days.
Transfected N2a cells were rinsed twice with ice-cold
PBS, lysed in homogenization buffer (50 mM Tris-Cl,
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pH 7 . 4 , 1 5 0 mM NaC l , 1% no n y l p h e n o x y
polyethoxylethanol (NP-40), 10% glycerol, 1 mM ethyl-
ene glycol tetraacetic acid (EGTA), 20 mM NaF, 1 mM
Na3VO4, 5 μM OA and protease inhibitor cocktail (Roche
Applied Science,Basel, Switzerland) and incubated on ice
for 30 min. After centrifugation at 16000×g at 4 °C for
20 min, the supernatant was collected and precleared with
Dynabeads Protein G (Thermo Fisher Scientific; Dreieich,
Germany) for 1 h at 4 °C. The lysates were incubated with
control IgG or anti-His or DA9 antibodies overnight with
constant rotation at 4 °C. Afterwards, Dynabeads Protein
G was added to the lysates and incubated at 4 °C for 1 h.
The beads were collected using a magnet and were
washed four times with cold PBS, resuspended in
Laemmli sample buffer, and analyzed by SDS-PAGE
followed by Western blotting with Tau antibody K9JA.
For in vitro immunoprecipitation, recombinant proteins
(50 μM hTau40, 200 μM F3ΔKPP or a combination of both
at 1:4 ratio) were incubated at 37 °C for at least 48 h in the
presence or absence of 12.5 μM heparin (16 K). The reac-
tion mixtures were incubated with control IgG or DA9 an-
tibodies overnight with constant rotation at 4 °C in 1× Tris-
buffered saline containing 0.05% Tween-20 Detergent
(TBST). Afterwards, Dynabeads Protein G was added to
the reaction mixtures and incubated at 4 °C for 3 h. The
beads were collected using a magnet and were washed four
times with cold 1× TBST, resuspended in Laemmli sample
buffer, and analyzed by SDS-PAGE followed by western
blotting with Tau antibody K9JA.
To detect the interaction between tau variants and heparin,
recombinant proteins (50 μM hTau40, 200 μM F3ΔKPP or a
combination of both) were incubated at 37 °C for at least 48 h
(or directly without incubation at 37 °C) in the presence or
absence of 12.5 μM heparin (16 K). Afterwards, Dynabeads
Protein G were added to the reaction mixtures directly without
prior incubation with an antibody, and incubated at 4 °C for
3 h. The beads were collected using a magnet and washed four
times with cold 1× TBST, resuspended in Laemmli sample
buffer, and analyzed by SDS-PAGE followed by western blot-
ting with Tau antibody K9JA.
Turbidity Assays
Tau-induced microtubule assembly was monitored by 90° an-
gle light scattering at 350 nm in a Fluorolog spectrophotom-
eter (HORIBA). Ten micromolar PC-purified tubulin were
mixed with 5 μM Tau protein in RB buffer (100 mM
PIPES, pH 6.9, 1 mM DTT, 1 mM MgSO4, 1 mM EGTA,
1 mMGTP). Different concentrations of F3ΔKPP (0, 5, 20, and
40 μM) were mixed to the reaction mixture and the polymer-
ization started by transferring the ice-cold tubulin/Tau solution
to the 37 °C warm cuvette holder at time point 0 min.
C. elegans Methods
Pan-neuronal snb-1 promoter (gift of Dr. B.C. Kraemer,
Seattle, WA) was used to drive the expression of cDNA con-
struct encoding the F3ΔKPP fragment. Transgenic arrays ex-
pressing F3ΔKPP fragment were generated by injecting Psnb-
1::F3ΔKPP (50 ng/μl) plasmid along with the selection marker
Pofm::dsRed (50 ng/μl) (gift of Dr. Naoki Hisamoto, Nagoya
University) into the gonad of N2 wild-type strain (Bristol).
Integration of transgene arrays into C. elegans genome was
achieved by UV irradiation (300 J/m2) and the resulting stable
lines were out-crossed to N2 (Bristol) at least five times.
Worm cultures were maintained according to the standard
protocols [19]. Strains used were: PIR30: pirIs30[Psnb-
1::F3ΔKPP-low; Pofm::dsRed], PIR31: pirIs31[Psnb-
1::F3ΔKPP-high; Pofm-2::dsRed], CK10: bkIs10[Paex-
3::hTau1N4R V337M; Pmyo-2::gfp] (gift of Dr. B.C.
Kraemer, Seattle, WA), PIR32: pirIs30;bkIs10, PIR33:
pirIs31;bkIs10, CZ1197: juIs73[Punc-25::gfp]III (gift of Dr.
E. Lundquist, Lawrence, KS), PIR34: pirIs32;juIs73, PIR35:
pirIs32;juIs73, jsIs609:Is:[Pmec-4::MLS::gfp] (gift of Dr.
Nonet, St Louis, MO), PIR36: pirIs32;jsIs609, PIR37:
p i r I s 33 ; j s I s 609 , P IR5 : p snb -1 : : p i r I s 5 [Psnb -
1::hTau40A152T-low;Pmyo-2::gfp], PIR38: pirIs5;pirIs31.
Behavioral Assay
The frequency of body bending (thrashes) was counted
for 30 s after transferring the synchronized animals from
each transgene in 20 μl of M9 buffer (22 mM KH2PO4,
42 mM Na2HPO4, 86 mM NaCl and 1 mM MgSO4) on a
glass slide and allowing them to settle for 1 min [20]. For
micrographs, 1-day old worms were allowed to crawl for
10 min and photographed using an Olympus SZH10 fitted
with SC30 camera.
Protein Extraction and Immunoblotting
For total worm lysates, 50 worms were dissolved in 30 μl 1×
Laemmli buffer, boiled at 90 °C in a shaker for 10 min and
loaded onto a 17% polyacrylamide gel for western blotting. To
isolate the insoluble Tau, worm pellets were resuspended in
high-salt RAB buffer [100 mM 2-(N-morpholino)
ethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgSO4,
20 mMNaF] and lysed by sonication (6 × 10 s, 10 s break) on
ice. Lysates were centrifuged at 40000×g for 40 min to yield
the resulting supernatant as the soluble RAB fraction. The
RAB pellet was suspended in RAB + 1 M sucrose buffer,
centrifuged for 20 min at 40000×g, and the supernatant was
discarded. The resulting pellet, after brief washing, was solu-
bilized in urea containing buffer (UREA) [30 mM Tris, 7 M
urea, 2 M thiourea, 4% CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate), pH 8.5]. All buffers
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contained Complete Protease Inhibitor Mixture 3× (Sigma-
Aldrich P8340, Hamburg, Germany), 1 μM Okadaic acid
and 0.5mMPMSF. Equal amounts of protein from eachworm
sample were loaded in separate gels, blotted and probed with
antibodies against tau or the loading control tubulin. The fol-
lowing antibodies were used for immunoblotting: DM1α-
tubulin (1:500; Sigma), K9JA (1:20,000; no. A0024; Dako),
peroxide-conjugated secondary antibodies, and ECL solution
(Thermo Scientific) were used to visualize the blots. AIDA
software was used to perform densitometry.
Survival Assay
To prevent mixing of the generations, worms were transferred
every second day to freshly seeded NGM plates until the fer-
tility period was over. Survival assay was carried out at 20 °C
and worms were scored every 1–2 days until death with L4
stage annotated as day 0. Animals were judged as dead if they
did not respond to a gentle touch or push.
Imaging
Steady-state imaging of GFP-tagged mitochondria in
mechanosensory neurons was performed by mounting worms
on 2% agarose pads after anesthetizing in 50 mM sodium
azide. Images were acquired at × 63 in two different regions,
proximal part (~ 80 μm axonal part adjacent to cell body) and
mid-region (beyond ~ 80 μm away from the cell body), using
a Zeiss epifluorescence microscope equipped with a CCD
(Photometrics) camera. To visualize the GABAergic motor
neurons, young immobilized adults (15 mM sodium azide)
were mounted on glass slides with 2% agarose pads and im-
aged at × 20 or × 40 using LSM 700 (Zeiss).
Results
β-Sheet Breaker Tau Fragment (F3ΔKPP) Reduces
Tau Aggregation
Our previous study had shown that the overexpression of
the repeat domain of Tau harboring an FTDP-17 mutation
ΔK280 (TauRDΔK) in N2a cells results in the proteolytic
generation of a fragment F3ΔK (Fig. 1) [17]. We generated
a β-sheet breaker Tau fragment via introduction of two pro-
lines into the two hexapeptide motifs of F3ΔK, yielding
F3ΔKPP (Fig. 1). We tested whether recombinant F3ΔKPP
fragment can influence the aggregation of TauRDΔK
in vitro using thioflavine S (ThS) to monitor Tau aggrega-
tion. F3ΔKPP alone does not form aggregates at all (black
curve, Fig. 2a), which is consistent with our previous stud-
ies showing that the introduction of twoβ-breaking prolines
into the two hexapeptides disrupts Tau aggregation. The
aggregation of TauRDΔK shows kinetics of nucleated assem-
bly with an exponential phase followed by a plateau phase
(red curve, Fig. 2a). F3ΔKPP decreases the rate of TauRDΔK
aggregation in a concentration-dependent manner. At low
concentrations (10 μM and 20 μM), the effect is small, and
roughly similar plateau values are reached (olive and blue
curves, Fig. 2a). In contrast, higher concentrations (40 μM
and 80 μM, purple and green) of F3ΔKPP noticeably de-
crease the assembly rate.
To further confirm that F3ΔKPP treatment affects the
aggregation of TauRDΔK, we separated soluble and insol-
uble Tau at the end of the incubation period via centrifu-
gation and quantified their amounts by SDS-PAGE (Fig.
2b). When TauRDΔK was incubated alone, ~ 60% of the
protein formed aggregates (Fig. 2b, lane 2 and Fig. 2c, bar
1, red). In agreement with the results of the TauRDΔK
aggregation kinetic assay, addition of higher concentra-
tions of F3ΔKPP (40 μM and 80 μM) markedly reduces
the aggregation of TauRDΔK, such that only 10% of
TauRDΔK appeared in the insoluble fraction (Fig. 2b,
lanes 8 and 10 and Fig. 2c, bars 4,5, red). These results
were corroborated by atomic force microscopy (AFM)
analysis, which showed a reduction of fibrillar structures
formed by TauRDΔK in the presence of F3ΔKPP (Fig. 2d,
compare top and middle panel). As expected, F3ΔKPP
alone did not show any fibrillary structures (Fig. 2d,
bottom panel).
F3ΔKPP Reduces hTau40-Induced Microtubule
Assembly
Being a microtubule-associated protein, Tau plays an impor-
tant role in microtubule assembly. We therefore examined
whether F3ΔKPP interferes with this physiological function
of Tau. Microtubule polymerization assays were performed
with or without different concentrations of F3ΔKPP. Tubulin
(at 10 μM) without Tau served as a negative control, as it is
unable to self-assemble into microtubules below the critical
concentration (Fig. 3, curve 1, green). Similarly, F3ΔKPP alone
is also unable to induce microtubule assembly (Fig.3, curve 2,
olive). In the presence of full-length Tau (5 μM hTau40),
tubulin polymerizes within about 8 min (Fig. 3, curve 5,
red). At 1:1 concentration (5 μM hTau40 + 5 μM F3ΔKPP),
microtubule assembly was slightly more efficient (Fig. 3,
curve 6, black). However, at higher concentrations of
F3ΔKPP, the rate and extent of polymerization decreased in a
concentration-dependent manner (Fig. 3, curve 4, purple for
20 μM F3ΔKPP and curve 3, blue for 40 μM F3ΔKPP).
This was verified by electron microscopy (EM), which
showed less microtubules that were often shorter and dec-
orated with protein clumps when Tau (5 μM) and F3ΔKPP
(20 μM) was added (Fig. 3b, right image) compared to
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Fig. 2 F3ΔKPP reduces TauRDΔK aggregation in vitro. TauRDΔK (10 μM,
upper band) was induced to aggregate with heparin (2.5 μM) in the
absence or presence of different concentrations of F3ΔKPP (lower band)
for up to 24 h. a The extent of aggregation asmeasured by the thioflavin S
fluorescence assay. All the measurements were performed in triplicate,
n = 3. b Pellet assay showing the distribution of soluble and aggregated
TauRDΔK (10 μM) alone (lanes 1, 2) or in the presence of F3ΔKPP 10 μM
(lanes 3, 4), 20 μM (lanes 5, 6), 40 μM (lanes 7, 8) and 80 μM (lanes 9,
10) at the end of incubation (S denotes the soluble fraction, P is the
insoluble pellet fraction). c Densitometry quantification of the soluble
(blue bars) and the insoluble (red bars) TauRDΔK from the gel shown in
(b). Note the suppression of TauRDΔK aggregation at higher F3ΔKPP
concentrations (40 μM & 80 μM, red bars 8, 10). The results are from
3 different gels. One-way ANOVAwas applied for multiple comparisons.
Error bars denote SD. (ns, non-significant, **p < 0.001). d In vitro
aggregation of TauRDΔK (10 μM) visualized using AFM in the absence
(top panel) or presence (middle panel) of F3ΔKPP (80 μM). 1–2 μM
protein was diluted in PBS and placed on mica for imaging. No
filamentous structures are seen in the presence of F3ΔKPP. F3ΔKPP
(80 μM) alone also does not form filamentous structures (bottom panel)
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F3ΔKPP Reduces Tau Aggregation and Cytotoxicity
in a Cell Model of Tau Aggregation
Next, we examined whether F3ΔKPP can inhibit Tau aggrega-
tion in cells. It is known that TauRDΔK forms aggregates in
N2a cells [17]. Therefore, we tested whether co-expression of
F3ΔKPP with TauRDΔK influences the aggregation of TauRDΔK
in N2a cells. We used the ThS staining to visualize the Tau
aggregates. When TauRDΔK is expressed alone, ~ 20% of cells
are positive for ThS (Fig. 4a, upper panel 1–3, Fig. 4b, bar 1).
The co-expression of F3ΔKPP reduces the ThS positive cells to
~ 9% (Fig. 4a, bottom panels 4–6, Fig. 4b, bar 2). We also
evaluated Tau aggregation using sarkosyl extraction to sepa-
rate soluble and insoluble Tau. Consistent with our previous
studies [18], the expression of TauRDΔK in cells results in its
fragmentation (generating fragments F2ΔK, F3ΔK) which then
nucleates Tau aggregation (Fig. 4c, lane 3). Notably, the co-
expression of F3ΔKPP inhibits the fragmentation of TauRDΔK
by cellular proteases, as no F3ΔK fragment was observed in
the pellet (Fig. 4c, lane 5). Accordingly, the aggregation is
reduced in the presence of F3ΔKPP (Fig. 4d, bar 2 in red).
Our previous studies have shown that the aggregation of
Tau induces cell death in N2a cells [17, 21]. We therefore
assessed whether F3ΔKPP could rescue Tau aggregation-
induced cell death. We monitored cell death via nuclear stain-
ing with EthD. When TauRDΔK was expressed alone, 11%
(11.1 ± 2.8%) of cells stained positive for EthD (Fig. 4e, upper
panel 1–4, Fig. 4f, bar 1 in red). However, when F3ΔKPP was
co-expressed with TauRDΔK, only 4.5% (4.5 ± 2.6%) of cells
showed EthD staining (Fig. 4e, bottom panel 5–8, Fig. 4f, bar
2 in gray). Moreover, consistent with our previous studies, the
majority of the ThS positive cells were stained by EthD (Fig.
4e 1,2,4 and Fig. 4e 5,6,8), pointing to cytotoxicity induced by
TauRDΔK aggregation. Thus, F3ΔKPP reduces TauRDΔK-in-
duced cytotoxicity via inhibiting its aggregation.
F3ΔKPP Suppresses Tau Pathology in an In Vivo
C. elegans Model
Next, we turned to an in vivo model to test the protective
efficacy of F3ΔKPP fragment. We used the TVM C. elegans
model that expresses human 1N4R-TauV337M pan-neuronally
1 μm 1 μm 
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Fig. 3 F3ΔKPP slightly reduces
hTau40-induced microtubule
assembly. Microtubule assembly
was measured by light scattering
at 350 nm in the absence or
presence of hTau40 with or
without different concentrations
of F3ΔKPP. a Tubulin and hTau40
concentration was 10 μM and
5 μM respectively. The ratios
between the concentration of
hTau40 and F3ΔKPP were 1:1,
1:4, and 1:8. Note that F3ΔKPP
reduces hTau40-induced
microtubule assembly by ~ 50%
(curves 4 and 3, purple and blue).
Tubulin without Tau (curve 1,
green) or with F3ΔKPP alone
(20 μM; curve 2, ochre) does not
assemble in these conditions
either. b Microtubule (10 μM)
assembly induced by Tau (5 μM)
visualized by negative stain
electron microscopy in the
absence (left panel) or presence
(right panel) of F3ΔKPP (20 μM).
Microtubules are reduced with
F3ΔKPP and become more fragile
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[22]. This worm develops progressive motor dysfunction,
neurodegeneration and accumulates detergent insoluble Tau
aggregates. Since the protective effects of F3ΔKPP were seen
at higher stoichiometric ratios, we generated a transgenic
C. elegans line F3ΔKPP-lo expressing F3ΔKPP pan-
neuronally at low levels, and another line F3ΔKPP-hi express-
ing F3ΔKPP at higher levels. These lines were then individu-
ally crossed with TVM resulting in double transgenic lines
TVM;F3ΔKPP-lo and TVM;F3ΔKPP-hi. We first assessed total
Tau levels in the parental TVM worm and the double transgen-
ic TVM;F3ΔKPP-lo and TVM;F3ΔKPP-hi worms, using the
K9JA antibody which recognizes an epitope common to both
the full-length Tau as well as the repeat fragment F3ΔKPP.
Double transgenic TVM;F3ΔKPP-lo and TVM;F3ΔKPP-hi
worms show comparable Tau levels as the single transgenic
parental TVM worm (Fig. 5a, lanes 2–4, Fig. 5b, bars 1–3).
TVM worms show progressive motor dysfunction as seen
by the distorted serpentine tracks left on the bacterial layer and
lower thrashing rate when placed in liquid compared to non-
transgenic control worms (compare Fig. 5c (1, 2) Fig. 5d, bars
1, 2). To check the protective effects of F3ΔKPP, we compared
the motor function of these worms. F3ΔKPP when co-
expressed at higher levels in TVM;F3ΔKPP-hi results in im-
proved motor function as seen by the near serpentine tracks
e f
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Fig. 4 F3ΔKPP reduces TauRDΔK aggregation and cytotoxicity in N2a
cells. N2a cells were transfected with TauRDΔK or co-transfected with
TauRDΔK and F3ΔKPP for 2 days. a Thioflavin S (ThS) staining of Tau
aggregates in N2a cells. Tau was monitored by immunostaining using a
pan-Tau antibody K9JA (red panel 2 and 5). b Quantification of the ThS
positive cells in relation to the Tau-expressing cells shown in (a). F3ΔKPP
strongly reduces ThS positive cells. (t test, n = 3; * p < 0.05). c Western
blot analysis (17% PAGE, Tau antibody K9JA) of sarkosyl soluble (S)
and insoluble (P) TauRDΔK in the absence (lanes 2, 3) or presence (lanes
4, 5) of F3ΔKPP. d Densitometry quantification of insoluble TauRDΔK
(lanes 3 and 5) of the blot shown in (c). Note the strong reduction (~
60%, red bar) of aggregated TauRDΔK by co-expression of F3ΔKPP.
(unpaired t test, n = 6; p = 0.0624). e Cell death monitored by nuclear
staining with Ethidium Homodimer (EthD). Tau expression was
determined by immunolabeling with antibody K9JA (panel 3 and 7),
Tau aggregation by ThS staining (green), and cell death by EthD
staining (blue). Note: that cell death (blue) was dramatically reduced by
the co-expression of F3ΔKPP (t test, SD, *p < 0.05). f Quantification of
cells positive for EthD staining shown in E. Cell death was reduced by the
co-expression of F3ΔKPP (t test, SD, *p < 0.05)
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left by this worm and higher thrashing rate in liquid compared
to the parental worm TVM (Fig. 5c4, Fig. 5d, bar 4). However,
TVM;F3ΔKPP-lo worm that co-expresses F3ΔKPP at lower
levels, failed to show any improvement in the motility (Fig.
5c3, Fig. 5d bar 3). TVM worms show reduced survival such
that TVM worms live ~ 50% shorter compared to non-
transgenic worms (Fig. 5e curve 1, red; curve 4, black). In
combination with F3ΔKPP-hi, however, 20% increase in the
median survival of the TVM worm is observed (Fig. 5e curve
3, green; Table 1).
GABAergic motor neurons that coordinate the motor
functions in worms show a compromised integrity in the
parental TVM worm [22]. These neurons can be visualized
by using a reporter transgene juIs73:[Punc-25::gfp]III
[23] that expresses GFP specific to this subset of neurons
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Fig. 5 F3ΔKPP at higher levels (F3ΔKPP-hi) improves the motor deficits in
a C. elegans Tau aggregation model (TVM). F3ΔKPP was expressed pan-
neuronally in worms transgenic for human 1N4R-TauV337M. TVM
expresses human 1N4R-TauV337M pan neuronally. TVM;F3ΔKPP-lo and
TVM;F3ΔKPP -hi are doubly transgenic for human 1N4R-TauV337M and
F3ΔKPP at low and high levels respectively. a Western blot of the total
worm lysates from synchronized 1-day-old adults using pan-Tau antibody
K9JA. Tubulin served as internal control. bQuantification of the total Tau
levels. One-way ANOVAwith Tukey’s test (n = 3, error bars denote SEM.
ns, non-significant). cMicrographs showing tracks left behind by 1-day-
old adults of the single and double transgenic worms. Non-transgenic
(non-tg) served as control. d Body bending frequency (thrashes) of
synchronized 1-day-old adults in liquid. Non-tg served as control, n =
40. One-way ANOVA with Tukey’s test was applied for multiple
comparisons. Error bars denote SEM. (ns, non-significant, **p < 0.01).
eRepresentative survival curves of single- TVM, double- TVM;F3ΔKPP-lo,
and TVM;F3ΔKPP-hi transgenic worms, non-tg served as control. Mantel-
Cox log-rank test was performed to determine the statistical differences
between genotypes
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hi worms were crossed into this reporter strain to visualize
the motor neurons in these worms. TVM worms show sig-
nificant neurodegeneration in the form of gaps in the dor-
sal and ventral nerve cords already at day 1 (~ 2 gaps)
compared to non-tg reporter worms (~0.04 gaps). This
does not differ from the TVM;F3ΔKPP-lo worms which
also show a similar level of damage in these neurons
(~ 1.96 gaps) (Fig. 6a (2, 3), Fig. 6b, bars 2,3). On the
other hand, TVM;F3ΔKPP-hi worms with higher F3ΔKPP
levels show reduced neurodegeneration of the nerve cords
(~ 1.08 gaps) (Fig. 6a4, Fig. 6b, bar 4). Thus an improve-
ment in the integrity of motor neurons is consistent with
an enhanced motility in TVM;F3ΔKPP-hi worms.
Since F3ΔKPP inhibited Tau aggregation in vitro and in cell
culture, we set out to investigate the status of insoluble Tau, a
pathological hallmark of human Tauopathies that is also reca-
pitulated by TVM worms [22]. TVM worms accumulate deter-
gent insoluble Tau in their neurons. After extracting the solu-
ble fraction, the insoluble Tau can be solubilized using a buffer
with increasing solubilizing strength. Therefore, worm lysates
from TVM, TVM;F3ΔKPP-lo, and TVM;F3ΔKPP-hi were sequen-
tially extracted by homogenizing the respective worm pellets
first in a high salt containing RAB buffer, resulting in the
soluble Tau fraction. The remaining Tau fraction, which cor-
responds to the insoluble Tau, was then isolated using urea



























































Fig. 6 F3ΔKPP-hi reduces
morphological defects and
suppresses the Tau aggregation in
TVM. a Fluorescence micrographs
of GABAergic motor neurons in
non-tg (1), TVM (2),
TVM;F3ΔKPP-lo (3), and
TVM;F3ΔKPP-hi (4). Animals
have ventral side oriented up.
Arrowheads show gaps in the
ventral and dorsal cord. bNumber
of gaps quantified in the neural
cords of 1-day-old adults. Error
bars denote SD. For comparison,
one-way ANOVAwith Tukey’s
test was applied (n = 25, ns, not
significant, **P < 0.01). c
Sequentially extracted Tau from
worm lysates of mixed stage
animals resolved on 17% PAGE
and immunoblotted using pan-
Tau K9JA antibody. Tubulin
served as a loading control. d
Densitometry quantification of
the insoluble Tau. TVM;F3ΔKPP-hi
(insoluble panel, lane 4) shows
reduced insoluble Tau (~ 50%).
One-way ANOVAwith Tukey’s
test (n = 3, error bars denote SEM.
ns, non-significant, ***P < 0.001)
Table 1 Statistical analysis of
life-span assay performed as in
Fig. 5e legend




Non-tg 22 70/120 – < 10−4
TVM 11 100/120 < 10−4 –
TVM;F3ΔKPP-lo 12 98/120 < 10−4 < 10−3
TVM;F3ΔKPP-hi 15 103/120 < 10−4 < 10−4
Mol Neurobiol
with higher F3ΔKPP levels show a striking decrease in the
detergent insoluble Tau aggregates compared to TVM and
TVM;F3ΔKPP-lo (Fig. 6c lower panel blot of insoluble
protein, compare lane 4 with lanes 2, 3). Thus the fragment
F3ΔKPP shows protection by reducing the accumulation of
insoluble Tau in TVM worm neurons, in agreement with the
results from in vitro and mammalian cell culture experiments
described above.
Tau (both soluble monomeric and insoluble aggregates) is
known to interfere with the axonal traffic in cell culture and
animal models [24, 25] which leads to a disrupted localization
of axonal cargoes. The fact that the insoluble Tau levels are
reduced in TVM;F3ΔKPP-hi worms prompted us to look at the
mitochondrial distribution. We generated mitochondrial re-
porter strains using jsIs609 worms [24] that express GFP-
labeled mitochondria in six mechanosensory neurons.We per-
formed the static imaging of GFP puncta in proximal and mid-
region of the mechanosensory neurons in all three worm lines
in 1- and 3-day-old adults, using a non-tg reporter strain as
control (see BMaterials and Methods^). Schematics in Fig. 7a
depict neurons with a normal and an abnormal mitochondrial
distribution. The mitochondrial distribution in the parental
TVM worm neurons differs from those in the non-transgenic
reporter worms at both time points, with fewer mitochondria
in proximal and mid regions of axons. Notably, the distribu-
tion is much more affected in the mid regions of axons to-
wards the distal end (Fig. 7b, c compare top- and mid-panel,
Fig. 7d, e, bars 1–4). Furthermore, F3ΔKPP co-expression im-
proves the mitochondrial distribution towards the wild-type
level. Thus, TVM;F3ΔKPP-hi (Fig. 7b c compare mid- and low-
er panel, Fig. 7d, e, bars 3–6) but not TVM;F3ΔKPP-lo (Sup
Fig. 1A, B compare mid- and lower-panel, Sup Fig. 1C, D 3–
6) worms show an increased number of mitochondria in both
the proximal and the mid-regions of neurons. We conclude
that a reduced insoluble Tau load in combination with an
improved cargo localization in the TVM;F3ΔKPP-hi neurons
improves the motility of these worms.
Peptide F3ΔKPP Does Not Directly Interact with Other
Tau Molecules in Cells
Previously we showed that the pro-aggregant fragment
F3ΔK can nucleate and promote the aggregation of full-
length Tau when co-expressed in N2a cells. Using
coimmunoprecipitation, we further demonstrated that this
occurs as a result of direct interaction between the two Tau
species [17]. Since F3ΔKPP can inhibit TauRDΔK aggrega-
tion, we asked whether this also results from a direct inter-
action with TauRDΔK. We tested this through an immuno-
precipitation assay. Since there is no antibody that can dif-
ferentially recognize F3ΔKPP and TauRDΔK, we co-
expressed F3ΔKPP with TauRDΔK-His in N2a cells, and
pulled down TauRDΔK-His with an antibody against the
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Fig. 7 F3ΔKPP-hi improves the mitochondrial distribution in C. elegans.
a Schematic representation of neurons with a normal and abnormal
mitochondrial distribution. b Representative images of GFP tagged
mitochondria in the mechanosensory neurons of non-tg reporter strain,
TVM and TVM;F3ΔKPP-hi animals at day 1 of adulthood. c Representative
images of GFP-tagged mitochondria in the mechanosensory neurons of
non-tg reporter strain, TVM and TVM;F3ΔKPP-hi animals at day 3 of
adulthood. d Average number of mitochondria quantified in the
proximal axon (~ 80 μm axonal part adjacent to cell body) at days 1
and 3. Student’s t-test for comparison (error bars denote SEM. **P <
0.01). e Average number of mitochondria quantified in the mid-region of
the axon (beyond ~ 80-μm length from cell body) at days 1 and 3.
Student’s t test for comparison (error bars denote SEM. ***P < 0.001)
Mol Neurobiol
(Fig. 8a, blot 1, lane 3, red circle), indicating that F3ΔKPP
does not interact with TauRDΔK-His. Similarly, to confirm
that F3ΔKPP does not interact with other Tau variants, we co-
expressed F3ΔKPP with hTau40 in N2a cells and pulled
down hTau40 with antibody DA9 that recognizes hTau40
but not F3ΔKPP. DA9 pulled down hTau40, but not F3ΔKPP
(Fig. 8a, blot 2, lane 3, red circle), suggesting that F3ΔKPP
does not interact with the full-length hTau40 either. These
results show that the anti-aggregant F3ΔKPP has a substan-
tially different conformation than the pro-aggregant F3ΔK
which precludes a direct interaction.
To explain why F3ΔKPP is able to inhibit aggregation
without binding to hTau40 or TauRDΔK one has to con-
sider the ternary system of polycationic molecules like
hTau40, TauRDΔK or F3ΔKPP, and the polyanionic heparin.
F3ΔKPP competes with hTau40 or TauRDΔK for the aggre-
gation inducer heparin and in the process sequesters it. To
test this hypothesis, we performed in vitro immunoprecip-
itation assays using recombinant proteins. We incubated
the recombinant 50 μM hTau40 and 200 μM F3ΔKPP (ra-
tio 1:4) at 37 °C in the presence or absence of heparin for
48 h, and pulled down hTau40 using the DA9 antibody.
DA9 pulled down both proteins hTau40 and F3ΔKPP only
when the two were incubated in the presence of heparin,
but not in the absence of heparin (Fig. 8b, blots 1, 2, lanes
3). These results suggest either that hTau40, F3ΔKPP and
heparin form a complex that can be pulled down by the
antibody DA9 directed against hTau40, or that heparin
binds to both Tau proteins and to the magnetic beads that
leads to pull down of the F3ΔKPP-Tau core. To confirm
this, the recombinant proteins—after incubating at 37 °C
for 48 h with or without heparin—were pulled down, this
time without an antibody. Surprisingly, both hTau40 and
F3ΔKPP were pulled down when heparin was present in
the solution, alone (Fig. 8c, blots 1, 2, lanes 2, red circles)
or in combination (Fig. 8c, blot 3, lane 2, red circles). In
the absence of heparin, none of the proteins was pulled
down, alone (Fig. 8c, blots 1, 2, lanes 4) or in combina-
tion (Fig. 8c, blot 3, lane 4). These results confirm that
heparin binds the recombinant proteins hTau40 and
F3ΔKPP, and is able to pull down both of them by binding
to the magnetic beads. Notably, heparin pulls down
F3ΔKPP almost completely compared to hTau40 as seen
by the thick bands at F3ΔKPP position in the pull-down
lanes (compare in Fig. 8c lane 2 in blots 1, 2, red circles).
Furthermore, direct pull-down experiments without prior
incubation of reaction mixtures at 37 °C led to the pull-
down of F3ΔKPP by heparin and not full-length Tau (Sup
Fig. S2, red circle). These results show that F3ΔKPP binds
heparin with a higher affinity than full-length Tau, consistent
with its higher specific positive charge. We therefore conclude
that F3ΔKPP inhibits the aggregation of TauRDΔK or hTau40
by a competition and sequestration effect whereby F3ΔKPP
preferentially binds and engages the aggregation inducers like
heparin. The effective reduction of aggregation inducers then
results in the inhibition of TauRDΔK or hTau40 aggregation.
Discussion
Tau aggregation characterizes Tauopathies including AD [26].
Numerous publications have reported that Tau aggregation
causes or accompanies a neurotoxic process, though the pre-
cise nature of this remains a matter of debate [2]. Accordingly,
suppressing Tau aggregation has long been proposed to be a
therapeutic approach for AD and other Tauopathies. The de-
velopment of low molecular weight inhibitors of Tau aggre-
gation has been challenging because of Tau’s variable confor-
mations and because protein-protein interaction interfaces are
generally flat and large, contrary to the deep cavities that small
molecules can bind to [27]. During the past decade, several
types of low MW compounds have been shown to inhibit Tau
aggregation in vitro and in vivo [24, 28–31]. Methylene blue
and its derivatives even entered clinical trials, although finally
failed at phase III [32]. The caveat is that compounds may
stabilize rather than disrupt the low-n oligomers (likely the
more toxic species), if they form binding pockets for low
MW compounds [33]. The increasing evidence that Tau olig-
omers are the most toxic species [34–36] may explain why
Fig. 8 F3ΔKPP does not interact directly with Tau40 or TauRDΔK to
prevent aggregation. N2a cells were co-transfected with F3ΔKPP and
TauRDΔK-His or hTau40 for 2 days. Antibody anti-His (blot A) and
DA9 (epitope: aa. 112–129) (blot B) were used to immunoprecipitate
TauRDΔK-His or hTau40 in the cell lysates respectively, using non-
specific IgG as control (A, B, lane 2). a Anti-His pulled down
TauRDΔK-His but not F3ΔKPP (blot 1, lane 3). Similarly, DA9 pulled
down hTau40 but not F3ΔKPP (blot 2, lane 3), indicating that there is no
direct interaction between F3ΔKPP and hTau40. b Recombinant hTau40
(50 μM) and F3ΔKPP (200 μM) were incubated at 37 °C for 48 h in the
presence (blot 1) or absence (blot 2) of 12.5 μM heparin (M.W. 16 K) in
BES buffer. Antibody DA9 (blots 1, 2, lane 3) was used to immunopre-
cipitate hTau40, using non-specific IgG as control (Ctrl-IgG, blots 1, 2,
lane 2). Note that in the presence of heparin, DA9 pulls down both
hTau40 and F3ΔKPP (blot 1, lane 3). However, in the absence of heparin,
DA9 pulls down only htau40 but not F3ΔKPP (blot 2, lane 3), indicating
an absence of a direct interaction between F3ΔKPP and hTau40. cHeparin
binds and pulls down F3ΔKPP and hTau40 in the absence of antibody.
Recombinant F3ΔKPP and hTau40 at the same concentrations as described
above were incubated at 37 °C for 48 h in the presence or absence of
heparin (16 K) in BES buffer and Dynabeads Protein G added to the
reaction mixtures afterwards. Note that hTau40 and F3ΔKPP can be pulled
down by heparin without requiring an antibody (blots 1, 2, 3, lane 2). In
the absence of heparin, neither of the proteins is pulled down (blot 1, 2, 3,
lane 4). Note the thick bands (red circle) corresponding to F3ΔKPP in the
pull-down lanes (blot 2, 3, lanes 2). This set of experiments shows (i)
heparin is able to bind F3ΔKPP and hTau40, (ii) heparin is able to bind the
beads and thereby pull down both the proteins either individually or in
combination, and (iii) the affinity is higher for F3ΔKPP than hTau40.
Hence, a direct interaction between F3ΔKPP and hTau40 is absent, but
the two interact indirectly via an aggregation inducer like heparin
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low MW Tau aggregation inhibitors have not yet succeeded
in clinical trials. There is thus a need to search for alternative
Tau aggregation inhibitors. Indeed, several groups are de-
veloping peptides targeting the two hexapeptide motifs of
Tau that govern the Tau aggregation process [8, 37, 38]. The
advantage to this approach is that the peptides occupy larger
and more specific interaction interfaces between Tau mole-
cules than low MW compounds, necessary to inhibit the
overall aggregation process.
Here, we show that a β-structure breaker Tau fragment
(F3ΔKPP) inhibits Tau aggregation and reduces Tau-induced
cytotoxicity in vitro and in vivo (Figs. 2, 4, 5, 6 and 7).
Surprisingly, F3ΔKPP does not inhibit Tau aggregation via
binding to Tau molecules, as no direct interaction of F3ΔKPP
with other Tau molecules was observed in vitro or in cul-
tured cells (Fig. 8). Therefore, it is likely that the inhibition
of aggregation is due to competition between F3ΔKPP and
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of F3ΔKPP with Tau molecules. Tau contains multiple hep-
arin binding sites as deducted from experiments using trun-
cated Tau constructs, but the repeat region is indispensable
for aggregation induced by heparin [39]. Despite being a
derivative of the Tau repeat domain, F3ΔKPP is incapable
of aggregation due to proline substitutions in the two
hexapeptide motifs that act as β-sheet breakers [5, 7].
Nevertheless, F3ΔKPP is expected to have a similar affinity
for polyanions like heparin. Indeed, in this study we show
that F3ΔKPP physically interacts with heparin. Notably, the
F3ΔKPP and heparin interaction is stronger than the full-
length Tau and heparin interaction (Fig. 8c, blot 2, lane 2,
compare with blot 1, lane 2, red circles). Thus, in a scenario
where aggregation is induced by polyanions like heparin,
F3ΔKPP preferentially binds and sequesters such aggrega-
tion inducers and thereby, the aggregation process is halted.
The factors causing Tau aggregation in vivo remain a
matter of debate. Post-translational modifications have been
reported to contribute to Tau aggregation. However, it is
unclear if they alone are sufficient to initiate Tau aggrega-
tion, given that no in vitro studies show the formation of
abundant Tau fibrils by post-translationally modified Tau in
the absence of cofactors [40]. Similarly, RNAmolecules are
capable of inducing Tau aggregation [41]. Recent studies
show that Tau forms part of the stress granule pathway,
which under pathological conditions leads to irreversible
aggregation of RNA binding proteins [42, 43]. The interac-
tion of Tau with ribosomes can inhibit protein synthesis and
this interaction is based on RNA’s and RNA binding pro-
teins [44]. Besides, Tau may undergo reversible phase tran-
sition in cells in the presence of various cofactors [45, 46].
This phase transition from free soluble tau to liquid droplets
might indeed represent early phases in the tau aggregation
process. Other factors that could potentially induce Tau ag-
gregation in vivo include sulphated glycosaminoglycans
like heparin sulphate, chondroitin sulphate and dermatan
sulphate. In the Alzheimer Disease brain, heparin sulphate
coexists with Tau in tangle bearing neurons [47, 48] and
neurons lacking neurofibrillary tangles may stain positive
for hyperphosphorylated Tau [39]. Moreover, reports that
sulphated glycosaminoglycans promote Tau phosphoryla-
tion by several kinases [49–51] and also prevent Tau bind-
ing to microtubules [52], suggest multiple effects favoring
Tau aggregation.
Under physiological conditions, Tau prefers to bind to
MT because of specific interactions, in addition to the elec-
trostatic interactions of oppositely charged polymers [53].
Furthermore, this interaction of Tau with MT actually pre-
vents interaction between the β-structure forming parts of
Tau and thereby prevents self-assembly of Tau [54]. Under
pathological conditions, the affinity of Tau to MT can be
reduced by post-translational modifications (e.g., phos-
phorylation). As such, Tau may be induced to aggregate
by inducers like RNA and/or heparin sulphate. Hence
F3ΔKPP, unable to contribute to filamentous assembly due
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a bFig. 9 Model of Tau aggregation
and competition with anti-
aggregant F3ΔKPP. Tau
aggregation can be induced
in vitro or in cells by cofactors
such as heparin, RNA, or other
polyanions (a). In such a scenario,
F3ΔKPP can compete with Tau
molecules by preferentially
binding and sequestering the
aggregation inducers. This might
prevent the formation of early
oligomers (dimers, trimers etc.)
(b). At low F3ΔKPP levels, suffi-
cient inducers are available so that
the aggregation of Taumay not be
disturbed. With increasing
F3ΔKPP levels, the inducers
available for Tau are reduced and
the aggregation of Tau is retarded
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Tau molecules for these aggregation inducers. Thus, when
the concentration of F3ΔKPP is low, the amount of the avail-
able inducers (e.g., heparin, RNA, or other cellular
polyanions) may be sufficient to trigger the aggregation of
other Tau molecules, but with increasing F3ΔKPP levels the
inducers available for other Tau molecules are reduced,
resulting in the reduction of aggregated Tau (Fig. 9). In
conclusion, we revealed that a β-structure breaker Tau frag-
ment (F3ΔKPP) can inhibit Tau aggregation and Tau-induced
cytotoxicity. This β-structure breaker Tau fragment may
have potential as a therapeutic approach for Tauopathies.
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